Published in Br J Cancer on March 24, 2003
Vitamin D and the anti-viral state. J Clin Virol (2011) 1.40
Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics (2009) 0.89
Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia. Indian J Urol (2012) 0.80
CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation. Int J Exp Pathol (2015) 0.78
Polymorphisms of vitamin D receptor gene TaqI susceptibility of prostate cancer: a meta-analysis. Onco Targets Ther (2016) 0.75
Association of VDR polymorphisms ( Taq I and Bsm I) with prostate cancer: a new meta-analysis. J Int Med Res (2017) 0.75
Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med (2000) 25.49
Cancer statistics, 1996. CA Cancer J Clin (1996) 6.85
Prediction of bone density from vitamin D receptor alleles. Nature (1994) 5.36
CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet (2002) 2.90
Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev (1993) 2.82
Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst (1998) 2.67
Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol (1995) 2.04
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res (1990) 2.00
Risk factors for prostate cancer. Ann Intern Med (1993) 1.90
Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology (1993) 1.68
The prostate: an increasing medical problem. Prostate (1990) 1.67
Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys (1988) 1.58
Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys (1997) 1.49
CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther (2000) 1.42
Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev (1998) 1.39
Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther (1999) 1.34
Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer (1999) 1.23
Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res (1996) 1.23
The association of benign prostatic hyperplasia and cancer of the prostate. Cancer (1992) 1.22
Comparison of methods for extracting DNA from formalin-fixed paraffin sections for nonisotopic PCR. Diagn Mol Pathol (1996) 1.20
Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev (1999) 1.20
Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. Cancer Res (1999) 1.15
Cancer statistics for African Americans, 1996. CA Cancer J Clin (1996) 1.11
Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study. Lancet (1974) 1.11
CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther (2000) 1.09
In vitro malignant transformation of cells derid from mouse prostate in the presence of 3-methylcholanthrene. J Natl Cancer Inst (1969) 1.03
Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol (1980) 0.99
"Spontaneous" neoplastic transformation in vitro: the ultrastructure of the tissue culture cell. Eur J Cancer (1970) 0.97
Epidemiologic study of prostatic cancer: preliminary report. Cancer Treat Rep (1977) 0.96
RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Natl Cancer Inst (1999) 0.94
Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet (1999) 0.92
Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat (1998) 0.92
Diet and cancer of the prostate: a case-control study in Greece. Int J Cancer (1999) 0.89
Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr J (2001) 0.88
CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep (2002) 0.88
Spontaneous in vitro neoplastic transformation of adult human prostatic epithelium. Science (1970) 0.86
CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics (2000) 0.86
Prostatic cancer after prostatectomy for benign disease. Cancer (1986) 0.85
Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Saudi Med J (2004) 0.85
Localised prostate cancer: can we do better? There have been some advances in local control, but little impact on survival. BMJ (2000) 0.84
More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst (2000) 0.79
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology (1989) 16.83
One thousand heart attacks in Grampian: the place of cardiopulmonary resuscitation in general practice. Br Med J (Clin Res Ed) (1987) 6.93
An improved rosetting assay for detection of human T lymphocytes. J Immunol Methods (1974) 6.54
Patient and general practitioner delays in acute myocardial infarction. Br Med J (Clin Res Ed) (1988) 4.94
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
Growth response of Nitrosomonas europaea to amino acids. J Bacteriol (1967) 4.26
Aircraft and road traffic noise and children's cognition and health: a cross-national study. Lancet (2005) 3.64
Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg (2001) 3.49
Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet (1997) 3.41
Case-control study of leukaemia and non-Hodgkin's lymphoma in children in Caithness near the Dounreay nuclear installation. BMJ (1991) 3.28
Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J Virol (1995) 3.18
Neighborhood poverty as a predictor of intimate partner violence among White, Black, and Hispanic couples in the United States: a multilevel analysis. Ann Epidemiol (2000) 3.17
Coronary artery ligation in anesthetized rats as a method for the production of experimental dysrhythmias and for the determination of infarct size. J Pharmacol Methods (1980) 3.10
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
Diversity of Conus neuropeptides. Science (1990) 2.78
Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer (2000) 2.73
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Postoperative wound infection: a computer analysis. Br J Surg (1971) 2.67
Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol (1990) 2.66
Matrix metalloproteinases in tumour invasion and metastasis. J Pathol (1999) 2.65
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (1995) 2.62
Management of women with low grade cytology: how reassuring is a normal colposcopy examination? BJOG (2014) 2.61
Genome-wide study of aging and oxidative stress response in Drosophila melanogaster. Proc Natl Acad Sci U S A (2000) 2.39
Olfactory deficits in schizophrenia. Biol Psychiatry (1988) 2.38
A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer (2000) 2.27
Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology (2001) 2.25
Drinking histories of self-identified lifetime abstainers and occasional drinkers: findings from the 1958 British Birth Cohort Study. Alcohol Alcohol (2006) 2.22
Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol (2000) 2.20
Accuracy of CPT evaluation and management coding by family physicians. J Am Board Fam Pract (2001) 2.20
Effect of mixed culture on Nitrosomonas europaea simulated by uptake and utilization of pyruvate. J Bacteriol (1966) 2.19
Respiratory symptoms questionnaire for asthma epidemiology: validity and reproducibility. Thorax (1993) 2.19
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group. Oncogene (1992) 2.13
Rural and urban differences in stage at diagnosis of colorectal and lung cancers. Br J Cancer (2001) 2.12
Distortion correction and robust tensor estimation for MR diffusion imaging. Med Image Anal (2002) 2.09
Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. BMJ (1995) 2.06
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest (1996) 2.02
Artifactual elevation of measured plasma L-lactate concentration in the presence of glycolate. Crit Care Med (1999) 1.99
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta (2002) 1.98
Assessment of cardiac output by the Doppler ultrasound technique alone. Br Heart J (1985) 1.97
Rural factors and survival from cancer: analysis of Scottish cancer registrations. Br J Cancer (2000) 1.97
The impact of the physical and urban environment on mental well-being. Public Health (2006) 1.96
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther (2013) 1.94
Improving the management of major trauma. Br J Anaesth (1990) 1.93
The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology (1993) 1.89
The Royal College of Physicians and interregnum politics. Med Hist (1975) 1.88
Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology (2000) 1.86
Variables influencing end-of-life care in children and adolescents with cancer. J Pediatr Hematol Oncol (2001) 1.78
Positron emission tomography in manganese intoxication. Ann Neurol (1989) 1.78
Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology (1997) 1.78
MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med (2004) 1.77
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol (2013) 1.77
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics (1999) 1.76
The role of annexins in tumour development and progression. J Pathol (2008) 1.75
Olfactory deficits in neuroleptic naive patients with schizophrenia. Schizophr Res (1993) 1.75
Repeated freezing and thawing of peripheral blood and DNA in suspension: effects on DNA yield and integrity. J Med Genet (1990) 1.74
Chronic anal ulceration due to nicorandil. Br J Dermatol (2005) 1.72
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics (2001) 1.70
Blood-flow in deep veins of leg. Recording technique and evaluation of methods to increase flow during operation. Br J Surg (1968) 1.69
Tumour markers of prognosis in colorectal cancer. Br J Cancer (1999) 1.68
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer (2006) 1.65
DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias. Am J Hum Genet (1987) 1.61
Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer (2007) 1.61
Inhaled fentanyl as a method of analgesia. Anaesthesia (1990) 1.60
Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur J Cancer (1998) 1.60
Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis (2003) 1.59
Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg (2003) 1.59
Aortic blood velocity measurement in healthy adults using a simple ultrasound technique. Cardiovasc Res (1983) 1.58
Use of emollients in dry-skin conditions: consensus statement. Clin Exp Dermatol (2013) 1.57
Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst (2000) 1.57
Impact of deprivation and rural residence on treatment of colorectal and lung cancer. Br J Cancer (2002) 1.55
Regulated underexpression and overexpression of the FliN protein of Escherichia coli and evidence for an interaction between FliN and FliM in the flagellar motor. J Bacteriol (1995) 1.53
Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost (2002) 1.52
Uptake and utilization of amino acids by resting cells of Nitrosomonas europaea. J Bacteriol (1967) 1.51
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med (1998) 1.50
Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer (2002) 1.49
Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med (1999) 1.48
Vascular complications after balloon and new device angioplasty. Circulation (1993) 1.46
Geographical, urban/rural and socioeconomic variations in nonmelanoma skin cancer incidence: a population-based study in Ireland. Br J Dermatol (2011) 1.45
p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res (1993) 1.45
Head injuries in children: a prospective five year follow-up. J Neurol Neurosurg Psychiatry (1977) 1.43
Laser capture microscopy. Mol Pathol (2000) 1.43
The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial. BJOG (2010) 1.42
Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer (1997) 1.42
Improved health care delivery in an inner-city well-baby clinic run by general practitioners. J R Coll Gen Pract (1986) 1.42
Embryonic stem cells and transgenic mice ubiquitously expressing a tau-tagged green fluorescent protein. Dev Biol (2000) 1.41
Estimated prevalence of dementia among elderly black and white community residents. Arch Neurol (1991) 1.39
CARDIOSPASM. Can Med Assoc J (1927) 1.38
Increasing patient knowledge, satisfaction, and involvement: randomized trial of a communication intervention. Pediatrics (1991) 1.37
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics (1999) 1.34
Improving physicians' preventive health care behavior through peer review and financial incentives. Arch Fam Med (1995) 1.34
Positron emission tomography in the early diagnosis of Huntington's disease. Neurology (1986) 1.33
Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem (1999) 1.33